Analyzing the genetic mutations linked with diseases such as cancer has yielded many potential drug targets. However, a significant number of these proteins are considered “undruggable,” mainly because their structure is too floppy for any kind of small-molecule drug to bind to it. Angela Koehler, an associate professor of biological engineering at MIT, has made it her mission to find ways to drug these targets. By taking aim at proteins that interact with the undruggable proteins, she can indirectly disable them or reduce their impact. This approach has already yielded…
